Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 323 participants.

Also called NCT01476475

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 323 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01476475
  • EudraCT 2011-002090-36
Other papers using this trial's data
  • Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial Diabetes care, 2016-09 DOI, PubMed 27284114, PMC5001145 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Chile, Czechia, Denmark, France, Germany, Hungary, Lithuania, Mexico, Poland, Romania, Slovakia, Sweden (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01476475. Randomized; no masking; primary purpose treatment. Start 2011-11 (registry gives no type); primary completion 2012-12 (actual). Results posted on 2017-02-10.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Insulin glargine /lixisenatide Fixed Ratio Combination
Intervention (Drug)
Insulin glargine
Intervention (Drug)
Metformin (Background drug)
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct01476475
Content hash
f056cd93ab03f798a6147cdca1a392c67f5d9cf466492845b7c17e26e2f8ad76